About Zentalis

We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Using our industry expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved patient outcomes.

Learn More

Pipeline

Candidate NameCand
PreclinicalPre
Phase 1Ph 1
Phase 2Ph 2
Phase 3Ph 3
CollaboratorsCollab
ZN-c3: Wee1 Inhibitor
Pfizer - GSK - Zentera logos
Pfizer - GSK - Zentera logos
Monotherapy

ZN-c3: Wee1 Inhibitor

Uterine Serous Carcinoma*
Uterine Serous Carcinoma+USC+
Biomarker-Driven*
Biomarker-Driven*Biomarker*
Solid Tumors
Solid TumorsSolid Tumors
Combination

ZN-c3: Wee1 Inhibitor

Osteosarcoma (+ gemcitabine)*
Osteosarcoma (+ gemcitabine)*Osteosarcoma
Ovarian Cancer (+ niraparib)
Ovarian Cancer (+ niraparib)Ov Cancer
Ovarian Cancer (+ chemo)
Ovarian Cancer (+ chemo)Ov Cancer
ZN-d5: BCL-2 Inhibitor
Zentera logo
Zentera logo
Monotherapy

ZN-d5: BCL-2 Inhibitor

AL Amyloidosis*
AL Amyloidosis*AL Amyloidosis*
AML + Non-Hodgkin’s Lymphoma
AML + Non-Hodgkin’s LymphomaAML + Non-Hodgkin’s Lymphoma
Combination

ZN-d5: BCL-2 Inhibitor

AML (+ ZN-c3)AML (+ ZN-c3)
ZN-c5: Oral SERD1
Zentera logo
Zentera logo
Monotherapy

ZN-c5: Oral SERD1

Breast Cancer
Breast CancerBrst Cancer
ZN-e4: EGFR Inhibitor1
SciClone logo
SciClone logo
Monotherapy

ZN-e4: EGFR Inhibitor1

NSCLC
NSCLCNSCLC
BCL-xL Degrader
Monotherapy

BCL-xL Degrader

Solid Tumors and Hematology MalignanciesSolid Tumors and Heme Malignancies

+ Registrational trial with FDA Fast Track designation
* Potentially registrational trial
1 Zentalis will discontinue the clinical development of ZN-c5 and ZN-e4 following completion of its existing clinical trials, which are closed to accrual, in these two programs.

Learn More

Join Zentalis